Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in San Diego, CA
NPI: 1144407115Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Get M.D. James's Phone Numberphone_androidMobile
Get M.D. James's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2007 - 2026
American Board of Internal Medicine
Medical Oncology
Heersink School of Medicine - Birmingham
uab.edu
Medical School
Until 2005
University of California (San Diego) Medical Center
Fellowship • Hematology and Medical Oncology
2009 - 2012
Residency • Internal Medicine
2005 - 2008
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 204 | 432 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 102 | 157 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 89 | 273 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 46 | 46 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 15 | 15 |
Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study.
Authors: Lyudmila Bazhenova
Publication Date: 2012-03-06
Authors: Sangwoo Kim, Jona Hattangadi-Gluth, James Murphy, Andrew Bruggeman, Ajay Pal Sandhu, Whitney Sumner, Andrew Sharabi
Journal: Front Oncol
Publication Date: 2021-04-30
Authors: Rana Mckay, Justin Shaya, Frederick Millard, Ava Saidian, Brent Rose, Tyler Stewart
Journal: Clin Genitourin Cancer
Publication Date: 2022-06-30
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Nivolumab, DRUG: Pembrolizumab, BIOLOGICAL: GEN-009 Adjuvanted Vaccine
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Pembrolizumab, OTHER: Pharmacological Study, PROCEDURE: Biospecimen Collection, OTHER: Clinical Observation, OTHER: Quality-of-Life Assessment, PROCEDURE: Computed Tomography, PROCEDURE: Cystoscopy, PROCEDURE: CT Urography
Lead Sponsor: Pharmacyclics LLC.
Intervention / Treatment: DRUG: docetaxel, DRUG: paclitaxel, DRUG: pembrolizumab, DRUG: ibrutinib, DRUG: everolimus, DRUG: cetuximab